☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC September Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Etoricoxib (Arcoxia®) has been rejected for the treatment of ankylosing spondylitis. The manufacturer failed to make a submission.

Brinzolamide/timolol eye drops (Azarga®) has been accepted for the treatment of raised intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. It was noted that the combination product allows patients to administer fewer drops at a modestly increased cost over separate administration of the constituents.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC September Update' by emailShare 'SMC September Update' on FacebookShare 'SMC September Update' on TwitterShare 'SMC September Update' on LinkedInShare 'SMC September Update' on reddit


No Comments to “SMC September Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.